Neurocrine Biosciences Inc (NBIX)
Number of days of payables
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ —
= —
The number of days of payables for Neurocrine Biosciences Inc is not provided in the data. This ratio typically measures the average number of days it takes for a company to pay its suppliers or vendors for goods and services purchased on credit. Without this information, it is difficult to analyze Neurocrine Biosciences Inc's payables management and liquidity position based on this specific ratio. It would be beneficial to obtain the missing data in order to perform a comprehensive analysis of the company's payment practices and efficiency in managing its accounts payable.
Peer comparison
Dec 31, 2024
Company name
Symbol
Number of days of payables
Neurocrine Biosciences Inc
NBIX
—
ADMA Biologics Inc
ADMA
29.91
Amgen Inc
AMGN
32.43
Bio-Techne Corp
TECH
20.58
Biogen Inc
BIIB
30.18
Gilead Sciences Inc
GILD
12.77
Halozyme Therapeutics Inc
HALO
10.21
Krystal Biotech Inc
KRYS
16.00
Moderna Inc
MRNA
26.55
Repligen Corporation
RGEN
12.03
Vericel Corp Ord
VCEL
131.69